The third day was one of the most exciting days of the AACR conference for the Oncology Central team as we eagerly waited to discover all the data from the plenary session. We have collated our highlights, let us know your thoughts in the comments below or on social media.
Remember you can find us at booth #4438, or follow our Twitter updates @OncologyCentral.
Rucaparib produces clinical response in certain pancreatic cancer patients
Maintenance therapy with the PARP inhibitor rucaparib (Rubraca®) has produced clinical responses amongst a subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy.
Esophageal cancers – combining virotherapy and radiotherapy shows early promise
Results from a Phase I clinical trial have indicated that a combination of virotherapy and radiotherapy results in a high response rate in esophageal cancer patients who may be unable to undergo more invasive treatments.
Surgery associated with increased survival in HER2+ Stage IV breast cancer patients
Results from a Phase lll clinical trial, assessing the effectiveness of a new targeted drug, taselisib, have demonstrated promising results against advanced breast cancer when combined with standard hormone therapy fulvestrant (Faslodex®).
Chris Babiarz is the last member of the Deming lab at #AACR19. He developed exciting data potentially identifying which patients with neuroendocrine tumors or small cell lung cancers are likely to benefit from immunotherapies. Really great work Chris!! @McArdleLab@UWCarbonepic.twitter.com/zPseI2p6lK